{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:44:39Z","timestamp":1793684679726,"version":"4.5.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["101076407"],"award-info":[{"award-number":["101076407"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["03-004- 2021-T045"],"award-info":[{"award-number":["03-004- 2021-T045"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.atherosclerosis.2025.119219","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:13:57Z","timestamp":1746710037000},"page":"119219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies"],"prefix":"10.1016","volume":"405","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8033-7298","authenticated-orcid":false,"given":"Anniek","family":"Strijdhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie G.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Bosmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim E.","family":"Dzobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal J.H.","family":"Kusters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nordin M.J.","family":"Hanssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Lutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W.M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom T.P.","family":"Seijkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119219_bib1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119219_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.119219_bib3","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119219_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093389","article-title":"Rheumatic manifestations in patients treated with immune checkpoint inhibitors","volume":"21","author":"Melissaropoulos","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2025.119219_bib5","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.119219_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1055\/s-0042-1749185","article-title":"Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials","volume":"122","author":"Ma","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2025.119219_bib7","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.atherosclerosis.2025.119219_bib8","unstructured":"Rohatgi A. WebPlotDigitizer. https:\/\/automeris.io\/WebPlotDigitizer.html2024."},{"key":"10.1016\/j.atherosclerosis.2025.119219_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119219_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119219_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093280","article-title":"Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice","volume":"9","author":"Cochain","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.119219_bib12","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ijcard.2012.12.085","article-title":"T-cell co-stimulation by CD28-CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.119219_bib13","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Investig"},{"key":"10.1016\/j.atherosclerosis.2025.119219_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.740531","article-title":"Stimulation of the PD-1 pathway decreases atherosclerotic lesion development in Ldlr deficient mice","volume":"8","author":"Grievink","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119219_bib15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00011-023-01703-5","article-title":"Blocking of programmed cell death-ligand 1 (PD-L1) expressed on endothelial cells promoted the recruitment of CD8(+)IFN-\u03b3(+) T cells in atherosclerosis","volume":"72","author":"Li","year":"2023","journal-title":"Inflamm Res"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.119219_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/CIRCRESAHA.124.324260","article-title":"Visualizing immune checkpoint inhibitors derived inflammation in atherosclerosis","volume":"135","author":"Lou","year":"2024","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119219_bib17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cvr\/cvs330","article-title":"CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE-\/- mice","volume":"97","author":"Ma","year":"2013","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.119219_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-Lymphocyte-Associated Antigen-4 prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119219_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jaccao.2022.09.005","article-title":"LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice","volume":"4","author":"Mulholland","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119219_bib20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncology"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.119219_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"Poels","year":"2020","journal-title":"Cells"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2025.119219_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37278","article-title":"Inhibition of CTLA-4 accelerates atherosclerosis in hyperlipidemic mice by modulating the Th1\/Th2 balance via the NF-\u03baB signaling pathway","volume":"10","author":"Zhao","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.atherosclerosis.2025.119219_bib23","article-title":"Disruption of the PGE(2) synthesis\/response pathway restrains atherogenesis in programmed cell death-1 (Pd-1) deficient hyperlipidemic mice","author":"Ricciotti","year":"2024","journal-title":"bioRxiv"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.119219_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41569-019-0227-9","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"16","author":"Basatemur","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119219_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00395-024-01033-5","article-title":"The interplay of collagen, macrophages, and microcalcification in atherosclerotic plaque cap rupture mechanics","volume":"119","author":"Jansen","year":"2024","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.119219_bib26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41577-019-0240-6","article-title":"Efferocytosis in health and disease","volume":"20","author":"Doran","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.atherosclerosis.2025.119219_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.104802","article-title":"Novel insights on the role of VCAM-1 and ICAM-1: potential biomarkers for cardiovascular diseases","volume":"84","author":"Kaur","year":"2022","journal-title":"Ann Med Surg"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.119219_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","article-title":"T cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119219_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.atherosclerosis.2012.07.033","article-title":"Persistent accumulation of interferon-\u03b3-producing CD8+CD56+ T cells in blood from patients with coronary artery disease","volume":"224","author":"Bergstr\u00f6m","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.119219_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2016.03.038","article-title":"Expansion of CD8(+) T cells lacking the IL-6 receptor \u03b1 chain in patients with coronary artery diseases (CAD)","volume":"249","author":"Hwang","year":"2016","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.119219_bib31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/01.ATV.16.8.1013","article-title":"Lymphocyte populations in atherosclerotic lesions of apoE -\/- and LDL receptor -\/- mice. Decreasing density with disease progression","volume":"16","author":"Roselaar","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119219_bib32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/01.ATV.0000201071.49029.17","article-title":"Diet and murine atherosclerosis","volume":"26","author":"Getz","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119219_bib33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/ATVBAHA.111.237693","article-title":"Animal models of atherosclerosis","volume":"32","author":"Getz","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.119219_bib34","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","article-title":"A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American heart association","volume":"92","author":"Stary","year":"1995","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2025.119219_bib35","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.120.048708","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries","volume":"142","author":"Calabretta","year":"2020","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.atherosclerosis.2025.119219_bib36","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.119219_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.016851","article-title":"Longitudinal assessment of subclinical arterial inflammation in patients receiving immune checkpoint inhibitors by sequential [(18)F]FDG PET scans","volume":"18","author":"Bacmeister","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2025.119219_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118595","article-title":"Arterial inflammation on [(18)F]FDG PET\/CT in melanoma patients treated with and without immune checkpoint inhibitors: check-flame I","volume":"398","author":"Polomski","year":"2024","journal-title":"Atherosclerosis"},{"issue":"41","key":"10.1016\/j.atherosclerosis.2025.119219_bib39","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025001170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025001170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T23:51:24Z","timestamp":1747957884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025001170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"alternative-id":["S0021915025001170"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119219","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119219"}}